In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Peregrine gains license for novel new anti-cancer compounds
Coulter acquires anti-cancer compounds
Celgene Licenses Rights To EntreMed For Tubulin Inhibitor Program
Galilaeus and Heidelberg Pharma agree on co-development of anti-cancer drugs
ActiveSight Signs Service Agreement with Celgene Corporation
Celgene and National Cancer Institute to collaborate on colorectal cancer trial
Antisoma to evaluate rainforest anti-cancer compounds from EcoBiotics Ltd
Celgene initiates Thalomid (tm) trials for non-small cell lung cancer
REPEAT/Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock